Marcellus + cancer   14

Cancer Treatment's Worst Side Effects Can Be Financial : Shots - Health News : NPR
Stress-inducing bills accumulate

More than 42 percent of the 9.5 million people diagnosed with cancer from 2000 to 2012 drained their life's assets within two years, according to a study published last year in the American Journal of Medicine. Cancer patients are 2.65 times more likely to file for bankruptcy than those without cancer, and bankruptcy puts them at a higher risk for early death, according to research.

But those statistics don't convey the daily misery of a patient with a life-threatening disease trying to navigate the convoluted financial demands of the U.S. health care system while simultaneously facing a roller coaster of treatment and healing.

Stephanie Wheeler, a professor at the University of North Carolina at Chapel Hill, said the number of bills coming from different providers can be overwhelming.
cancer  healthcare  health_insurance  bankruptcy  MedicareForAll  grade_A  grade_AA  NPR 
9 weeks ago by Marcellus
***** 42% of cancer patients spent entire life savings in 2 years after diagnosis, study finds | Advisory Board Daily Briefing
American Journal of Medicine: 42.4% of patients had spent all of their money during the first two years of treatment. After four years, the researchers found 38.2% of patients had depleted their life's assets.
* cancer patients spend an average of 11% of their total household income on expenses related to their treatment (with some patients spending up to a third of their income).
* A recent study found that financial insolvency is a clear risk factor for mortality—cancer patients who declared bankruptcy had a 79% greater risk of death than those who had not.
* Other research has found that patients experiencing financial distress also report poorer physical health, mental health, and satisfaction with their relationships.

The researchers determined that about 42.4% of patients had spent all of their money during the first two years of treatment. After four years, the researchers found 38.2% of patients had depleted their life's assets. The researchers estimated patients' average net worth fell by $92,098 after two years and by $51,882 after four years.

https://www.advisory.com/daily-briefing/2018/11/01/financial-toxicity

——————————————————————————————
42% of all cancer patients deplete their life's savings just two years after diagnosis. That an average $92k drop in net worth, plus an additional $52k in four years.

The "uninsured" rate is under 9% in this country. Most of these people going bankrupt from cancer treatments have health insurance, or at least started with it (but lost it after they became too ill to work).

And when you run out of cash, you're much more likely to die: cancer patients who declared bankruptcy had a 79% greater risk of death than those who had not.

The people most likely to avoid bankruptcy are older patients with substantial savings and [drumroll please] Medicare, which caps expenses at ~5k/year, and can't drop them due to inability to pay.

https://www.advisory.com/daily-briefing/2018/11/01/financial-toxicity
cancer  bankruptcy  MedicareForAll  healthcare  health_insurance  healthcare_price_gauging  grade_A  grade_AA  grade_AAA  study 
9 weeks ago by Marcellus
Measles virus for cancer therapy
Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional "spontaneous" tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore not susceptible to the virus. Serendipitously, attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their non transformed counterparts. For this reason, attenuated measles viruses are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models. The viruses can be engineered to enhance their tumor specificity, increase their antitumor potency and facilitate noninvasive in vivo monitoring of their spread. A major impediment to the successful deployment of oncolytic measles viruses as anticancer agents is the high prevalence of pre-existing anti measles immunity, which impedes bloodstream delivery and curtails intratumoral virus spread. It is hoped that these problems can be addressed by delivering the virus inside measles-infected cell carriers and/or by concomitant administration of immunosuppressive drugs. From a safety perspective, population immunity provides an excellent defense against measles spread from patient to carers and, in fifty years of human experience, reversion of attenuated measles to a wild type pathogenic phenotype has not been observed. Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway.
measles  vaccinations  cancer 
11 weeks ago by Marcellus
Why The US Has Better Cancer Survival Rates Than The Rest Of The World
Treatments that cost $200,000 per year are used to extend average life expectancy by 3–4 months in stage 4 cancers. Of course it's worth it for the minority of patients who are put into long term remission. But it doesn't help the others.

---------------
So with all of that said, yes, America has among the best cancer survival statistics because of an incredible abundance of high technology equipment and drugs, more extensive screening, and more aggressive treatment.

America also in general has better survival statistics when cancers are compared stage for stage. Of course there are exceptions. Japan survival statistics for stomach cancer are much better than American numbers.

Very expensive cancer treatments such as the new immunotherapies for cancer are more widely available in America than in countries with national healthcare where there are restrictions based on cost/benefit and budget caps.

The larger question is whether a society can afford to spend what America spends to get low single digit improvement in cure rates and and to prolong survival by a few months especially at the end of life.

Treatments that cost $200,000 per year are used to extend average life expectancy by 3–4 months in stage 4 cancers. Of course it's worth it for the minority of patients who are put into long term remission. But it doesn't help the others.
grade_A  grade_AA  grade_AAA  healthcare  health  health_insurance  cancer  us  USA  2017 
july 2019 by Marcellus
Doctors hail world first as woman’s advanced breast cancer is eradicated | Science | The Guardian
Simon Vincent, director of research at Breast Cancer Now, added: “This is a remarkable and extremely promising result, but we need to see this effect repeated in other patients before giving hope of a new immunotherapy for incurable metastatic breast cancer.
cancer  medicine 
june 2018 by Marcellus
Weed-Whacking Herbicide Proves Deadly to Human Cells - Scientific American
By using embryonic and placental cell lines, which multiply and respond to chemicals rapidly, and fresh umbilical cord cells, Seralini’s team was able to determine how the chemicals combine to damage cells.
Roundup  health  diet  cancer  Europe  study 
july 2016 by Marcellus
RoundUp Reality: Americans Are Exposed to a LOT More Glyphosate than Europeans - Robyn O'Brien
Globally, glyphosate use has risen almost 15-fold since so-called “Roundup Ready,” genetically engineered glyphosate-tolerant crops were introduced in 1996. Two-thirds of the total volume of glyphosate applied in the U.S. from 1974 to 2014 has been sprayed in just the last 10 years.
monsanto  GMO  roundup  cancer  health  Food 
february 2016 by Marcellus

Copy this bookmark:



description:


tags: